CXCR2 and neoplasm: The authors further highlighted the therapeutic potential for modulating TAMs in the TME by combining treatment with a Cxcr2 inhibitor with infusions of Cxcr2-KO activated monocytes, which further increased the efficiency of tumor inhibition [40].